Fengting Yan

Employment

• Swedish Cancer Institute

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer
  Investigational New Drugs 2026 DOI: 10.1007/s10637-026-01614-2
  +Save
• Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine
  The Oncologist 2026 DOI: 10.1093/oncolo/oyag330
  +Save
• Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146496
  +Save
• Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  Cancer Research Communications 2025 DOI: 10.1158/2767-9764.CRC-25-0019
  +Save
• Table 4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146466
  +Save
• Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146469
  +Save
• Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146472
  +Save
• Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146475
  +Save
• Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146478
  +Save
• Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
  2025 DOI: 10.1158/2767-9764.30146481
  +Save